Genome Environment Microbiome and Metabolome in Autism
Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY
GEMMA is a multicenter longitudinal observational study that follows children who are genetically at-risk of developing autism for their first three years of life, seeking to identify potential biomarkers predictive of autism development in the blood, stool, urine and saliva. The biomarkers identified in this project will contribute to a better understanding of the pathogenesis of ASD in at-risk children and possible solutions for alleviating and/or preventing ASD and ASD-related symptoms in patients in the future.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 6 months
Healthy Volunteers: f
View:
• Healthy newborns and infants less than 6 months of age who have not been introduced to solid foods (elementary formula feeding is permitted)
• First-degree relatives of ASD individuals (at least one sibling affected by ASD)
Locations
United States
Massachusetts
Massachusetts General Hospital for Children
RECRUITING
Boston
Other Locations
Ireland
National University of Ireland Galway
RECRUITING
Galway
Italy
The Azienda Sanitaria Locale Salerno
RECRUITING
Salerno
Contact Information
Primary
Victoria Kenyon, MHA
vakenyon@mgb.org
617-643-4366
Time Frame
Start Date: 2019-07-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 600
Treatments
Infants with ASD-affected sibling
Infants, enrolled at 0-6 months of age, who have a sibling diagnosed with ASD.
Authors
W. Allan Walker, Sarah Kadzielski, Alessio Fasano
Related Therapeutic Areas
Sponsors
Collaborators: Azienda Sanitaria Locale Salerno, National University of Ireland, Galway, Ireland
Leads: Massachusetts General Hospital